Pharma Pulse 11/18/24: An Overview of RFID, Moving More Modifies Mood & more

Peer Exchange: An Overview of RFID Within the Pharmaceutical Industry (Episode 1)

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, alongside a panel of experts, discussed the role of radio frequency identification (RFID) technology in the pharmaceutical and healthcare sectors. RFID is a technology that utilizes radio waves to automatically collect and transfer data, providing efficient tracking and tracing of products. This discussion covers the potential and challenges of RFID in the industry.

The panel consisted of Matt Campasano, Managing Director, Criterion Consulting; Sean O’Hearen; Founder & Principal Consultant, 1st Line Partners; Tim Marsh, Founder & Head of Strategy, MDB; and Bahar Aliakbarian, PhD, Associate Professor, Sr. Director of R&D, Axia Institute (at Michigan State University).

Moving More Modifies Mood. The Mounting Evidence for Exercise As an Antidepressant

Various treatment guidelines for depression recommend exercise, but they tend to be short on details.

Elon Musk Adds Microsoft to Suit Against OpenAI

In a new legal filing, the Tesla chief executive accuses the A.I. start-up of undermining antitrust law.

Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development

Perspectum announced that it has been awarded a 2024 U.S. Food and Drug Administration Drug Development Tool (DDT) Research Grant to evaluate a novel biomarker aimed at addressing the unmet needs of patients with rare diseases. This award highlights Perspectum’s steadfast commitment to supporting targeted therapies that improve patient care and quality of life.

ACTO on LinkedIn

This piece featuring Sanofi authors disussing the positive impact of #AI across many different areas of a business.

#pharma

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs